Azam Bozorgi1,2, Maryam Bozorgi2, Mozafar Khazaei3. 1. Department of Tissue Engineering, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. 2. Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. 3. Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. mkhazaei1345@yahoo.com.
Abstract
BACKGROUND: Breast cancer (BC) is a highly prevalent solid cancer with a high-rise infiltration of immune cells, turning it into a significant candidate for tumor-specific immunotherapies. Chimeric antigen receptor (CAR)-T cells are emerging as immunotherapeutic tools with genetically engineered receptors to efficiently recognize and attack tumor cells that express specific target antigens. Technological advancements in CAR design have provided five generations of CAR-T cells applicable to a wide range of cancer patients while boosting CAR-T cell therapy safety. However, CAR-T cell therapy is ineffective against breast cancer because of the loss of specified antigens, the immunosuppressive nature of the tumor and CAR-T cell-induced toxicities. Next-generation CAR-T cells actively pass through the tumor vascular barriers, persist for extended periods and disrupt the tumor microenvironment (TME) to block immune escape. CONCLUSION: CAR-T cell therapy embodies advanced immunotherapy for BC, but further pre-clinical and clinical assessments are recommended to achieve maximized efficiency and safety.
BACKGROUND: Breast cancer (BC) is a highly prevalent solid cancer with a high-rise infiltration of immune cells, turning it into a significant candidate for tumor-specific immunotherapies. Chimeric antigen receptor (CAR)-T cells are emerging as immunotherapeutic tools with genetically engineered receptors to efficiently recognize and attack tumor cells that express specific target antigens. Technological advancements in CAR design have provided five generations of CAR-T cells applicable to a wide range of cancer patients while boosting CAR-T cell therapy safety. However, CAR-T cell therapy is ineffective against breast cancer because of the loss of specified antigens, the immunosuppressive nature of the tumor and CAR-T cell-induced toxicities. Next-generation CAR-T cells actively pass through the tumor vascular barriers, persist for extended periods and disrupt the tumor microenvironment (TME) to block immune escape. CONCLUSION: CAR-T cell therapy embodies advanced immunotherapy for BC, but further pre-clinical and clinical assessments are recommended to achieve maximized efficiency and safety.
Authors: Lawrence G Lum; Archana Thakur; Zaid Al-Kadhimi; Gerald A Colvin; Francis J Cummings; Robert D Legare; Don S Dizon; Nicola Kouttab; Abby Maizel; William Colaiace; Qin Liu; Ritesh Rathore Journal: Clin Cancer Res Date: 2015-02-16 Impact factor: 12.531
Authors: Anke Janssen; Jose Villacorta Hidalgo; Dennis X Beringer; Paul Fisch; Jürgen Kuball; Sanne van Dooremalen; Febilla Fernando; Eline van Diest; Antonela R Terrizi; Peter Bronsert; Sylvia Kock; Annette Schmitt-Gräff; Martin Werner; Kerstin Heise; Marie Follo; Trudy Straetemans; Zsolt Sebestyen; Dmitry M Chudakov; Sofya A Kasatskaya; Felix E Frenkel; Sarina Ravens; Eric Spierings; Immo Prinz; Ralf Küppers; Miroslav Malkovsky Journal: Cancer Immunol Res Date: 2020-02-04 Impact factor: 11.151
Authors: James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg Journal: Blood Date: 2010-07-28 Impact factor: 22.113
Authors: Roberta Sommaggio; Elisa Cappuzzello; Anna Dalla Pietà; Anna Tosi; Pierangela Palmerini; Debora Carpanese; Lorenzo Nicolè; Antonio Rosato Journal: Oncoimmunology Date: 2020-06-11 Impact factor: 8.110